BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 17893700)

  • 21. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE.
    Litwin MS; Sadetsky N; Pasta DJ; Lubeck DP
    J Urol; 2004 Aug; 172(2):515-9. PubMed ID: 15247718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival.
    Hall SE; Holman CD; Wisniewski ZS; Semmens J
    BJU Int; 2005 Jan; 95(1):51-8. PubMed ID: 15638894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE.
    Latini DM; Chan JM; Cowan JE; Arredondo SA; Kane CJ; Penson DF; DuChane J; Carroll PR;
    Urology; 2006 Dec; 68(6):1242-7. PubMed ID: 17141841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M; Walker-Corkery E; Barry MJ
    J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men.
    Jeldres C; Suardi N; Walz J; Saad F; Hutterer GC; Bhojani N; Shariat SF; Perrotte P; Graefen M; Montorsi F; Karakiewicz PI
    Eur Urol; 2008 Jul; 54(1):107-16. PubMed ID: 17996358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting.
    Berge V; Thompson T; Blackman D
    Scand J Urol Nephrol; 2007; 41(3):198-203. PubMed ID: 17469027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans.
    Riley GF; Warren JL; Potosky AL; Klabunde CN; Harlan LC; Osswald MB
    Med Care; 2008 Oct; 46(10):1108-15. PubMed ID: 18815533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
    Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
    J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Partnership and outcomes in men with prostate cancer.
    Bergman J; Gore JL; Saigal CS; Kwan L; Litwin MS
    Cancer; 2009 Oct; 115(20):4688-94. PubMed ID: 19626653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in treatment costs for localized prostate cancer: the healthy screenee effect.
    Zeliadt SB; Etzioni R; Ramsey SD; Penson DF; Potosky AL
    Med Care; 2007 Feb; 45(2):154-9. PubMed ID: 17224778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor.
    Hu JC; Elkin EP; Krupski TL; Gore J; Litwin MS
    Cancer; 2006 Jul; 107(2):281-8. PubMed ID: 16779794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma.
    Denberg TD; Glodé LM; Steiner JF; Crawford ED; Hoffman RM
    BJU Int; 2006 Aug; 98(2):335-40. PubMed ID: 16879674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer incidence after localized therapy for prostate cancer.
    Moon K; Stukenborg GJ; Keim J; Theodorescu D
    Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of medicare health care delivery systems on survival for patients with breast and colorectal cancer.
    Kirsner RS; Ma F; Fleming L; Federman DG; Trapido E; Duncan R; Wilkinson JD
    Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):769-73. PubMed ID: 16614122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma.
    Brandeis J; Pashos CL; Henning JM; Litwin MS
    Cancer; 2000 Oct; 89(8):1792-9. PubMed ID: 11042575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
    Nguyen PL; Chen MH; Catalona WJ; Alexander BM; Roehl KA; Loeb S; D'Amico AV
    Cancer; 2008 Dec; 113(11):3146-52. PubMed ID: 18932254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of insurance and stage at diagnosis among patients aged 55 to 74 years in the national cancer database.
    Ward EM; Fedewa SA; Cokkinides V; Virgo K
    Cancer J; 2010; 16(6):614-21. PubMed ID: 21131794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.